News
ARUXF
0.017
NaN%
--
Acrux to Brief Investors on Women’s Health Hormone Therapy Strategy
TipRanks · 08/14 00:08
Acrux Seeks ASX Quotation for 200,000 Employee Scheme Shares
TipRanks · 08/13 11:08
Acrux Reports Lapse of 110,000 Performance Rights
TipRanks · 08/13 11:07
Acrux Highlights Female Testosterone Strategy at Bioshares Biotech Summit
TipRanks · 08/05 23:24
Acrux Completes $1.6m Share Placement and Confirms Regulatory Compliance
TipRanks · 07/29 00:34
Acrux Seeks ASX Quotation for 65.8 Million Additional Shares
TipRanks · 07/29 00:34
Acrux Director Increases Shareholding Through Exercise of Vested Rights
TipRanks · 07/23 23:42
Acrux Seeks ASX Quotation for Employee Incentive Shares
TipRanks · 07/23 23:28
Acrux Seeks ASX Quotation for New Shares Issued Under Employee Scheme
TipRanks · 06/25 05:17
Acrux Director Tim Oldham Increases Indirect Shareholding via Rights Exercise
TipRanks · 06/02 04:27
Acrux Director Increases Stake Through Exercise of Vested Rights
TipRanks · 06/01 23:54
Acrux Director Increases Shareholding Through Exercise of Equity Rights
TipRanks · 06/01 23:54
Acrux Performance Rights Lapse Trims Potential Share Dilution
TipRanks · 06/01 23:51
Acrux Details Milestone Structure for Australian Lenzetto Licensing Deal
TipRanks · 05/29 02:37
Acrux Expands Lenzetto Licensing to Australia in Deal Worth Up to AUD 5.4m
TipRanks · 05/27 23:18
Acrux Plans Major Equity Issue to Bolster Capital Base
TipRanks · 05/11 01:02
Acrux Secures $1.6m Placement to Advance Female Testosterone Program
TipRanks · 05/11 01:02
Acrux Seeks Trading Halt Ahead of Proposed Capital Raising
TipRanks · 05/07 00:18
Acrux Secures $0.55m Advance on FY26 R&D Tax Incentive to Support HRT Development
TipRanks · 03/11 23:18
Acrux Performance Rights Lapse After Reaching Expiry
TipRanks · 02/26 00:43
More
Webull provides a variety of real-time ARUXF stock news. You can receive the latest news about Acrux Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ARUXF
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.